RHRodney J. Y. Ho

Rodney J. Y. Ho

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rodney J. Y. Ho has a total of 154 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Novel Injectable Drug Combination Nanoparticle Containing 3 Antiretrovirals Designed for Human Immunodeficiency Virus Treatment: A First-in-Human Trial

    by Rachel A Bender Ignacio, Christine Jonsson, Simone Perazzolo, Zachary Stephen, Brett Hanscom, Eli Burnham, Phoebe Bryson-Cahn, Claborne Youngblood, Luqi Duan, Allysson Angeldekao, et al.

    Background: Long-acting antiretroviral therapy may improve adherence and decrease stigma, yet affordable combination formulations for global usage are lacking. The TLC-ART program engineered an injectable 3-drug combination in a novel nanoparticle (DcNP) product “TLC-ART 101,” composed of lopinavir (LPV), ritonavir (RTV), and tenofovir (TVF) and 2 lipid excipients. We report safety and pharmacokinetics from this first-in-human study. Methods: Three dose cohorts of people without human immunodeficiency virus (HIV) received a single subcutaneous dose of 1.5, 3.0, or 4.0 mL in an adaptive trial of up to 64 days. LPV, RTV, and TFV were measured over time in plasma, peripheral blood mononuclear cells (PBMCs), and lymph nodes. Results: All 12 participants completed the study. One participant experienced anaphylaxis, and 4 had nonserious hypersensitivity events (rash, lip swelling, generalized pruritus). All participants had grade 1–2 injection-site reactions. At the highest dose, median LPV half-life (T1/2) was 17 days, and LPV was detectable through 2 months in most participants. RTV T1/2 was 12 hours. Plasma TFV T1/2 was 3.5 days; TFV diphosphate was detected intracellularly through 14 days. Total exposure (area under the curve) was higher in PBMCs versus plasma for all 3 drugs. Conclusions: The first human application of this novel HIV DcNP resulted in detection of LPV through 2 months and TFV up to 4 days in plasma, and no meaningful prolongation of RTV. Systemic hypersensitivity was common, and although IgE elevation was not observed, additional mechanistic understanding is required prior to further development of this DcNP pipeline. Clinical Trials Registration: NCT05850728.

  • A novel all-in-one injectable composed of tenofovir alafenamide–dolutegravir-lamivudine exhibits long-acting plasma and cell drug persistence for 8 weeks

    by Zachary R. Stephen, Simone Perazzolo, Luqi Duan, Masa Eguchi, Baopin Tian, Keegan Klein, Loren Kinman, Rachele Delle Fratte, Kristina M. Adams Waldorf, Theresa Barton, et al.

    Objective: To investigate the novel 3-in-one long-acting injectable product composed of tenofovir alafenamide (TAF), dolutegravir (D), and lamivudine (L), as a complete TAF-DL product for pediatric HIV treatment. Design: TAF-DL sterile injectable product is assembled with 3-HIV drugs and amphipathic lipids. It is built on the drug-combination-nanoparticle (DcNP) platform via a well-defined manufacturing process. Plasma concentrations for all 3 drugs were determined in 12 juvenile nonhuman primates (NHP, M. nemestrina ) following subcutaneous administration. Safety parameters monitored. Results: Following a single dose of TAF-DL-in-DcNP , all drugs exhibited long-acting cell-and plasma profiles in juvenile NHP for 8 weeks. Time-to-peak occurred within 24 hr, for all drugs. Compared to free-soluble counterpart, DcNP formulation enhanced TAF, D and L half-life by 23, 5.8, 8.3-fold; and AUC by 41, 18, 3.1-fold. Cell targeting enabled by DcNP is noted as higher intracellular PBMC versus plasma concentration of TAF, tenofovir (T), D, L in NHP dosed with TAF-DL-in-DcNP product. Safety assessment in 12 juvenile-NHPs noted no injection site reactions, or change in weight, complete blood count, and serum chemistries over 8 weeks. Conclusions: Current 3-HIV oral drugs, TAF-DL is successfully transformed into a novel, single long-acting injectable product that may support once-every-two-month dosing. TAF-DL-in-Dc NP enhanced HIV host-lymphocyte drug exposure. With less than 24 hr to reach C max , the all-in-one product may overcome the need for an oral-lead-in typically required to initiate LA injectables. TAF-DL-in-DcNP product appears to be safe in juvenile NHPs.

  • Open Access

    Accelerating Generic Long‐Acting Antiretrovirals for Global HIV Treatment: Workshop Findings and a Roadmap to Access

    by Usman Arshad, Lobna Gaayeb, Henry Pertinez, Rajith K. R. Rajoli, Melynda Watkins, Parag Nimbolkar, Simone Perazzolo, Bharat Pagi, Annemarie Wensing, Saye Khoo, et al.

    The global HIV response aims for widespread availability of affordable, quality‐assured long‐acting antiretroviral (LA ARV) drugs to achieve sustained epidemic control, particularly in low‐ and middle‐income countries. This report summarizes key discussion points, findings, and outcomes from an international workshop on generic LA ARVs, held in Liverpool, United Kingdom, and co‐organized by the Long‐Acting/Extended‐Release Antiretroviral Resource Program (LEAP) and the Centre of Excellence for Long‐acting Therapeutics (CELT). The workshop brought together experts from across disciplines to evaluate the multifaceted challenges and opportunities for faster development and regulatory approval of affordable and accessible generic LA ARVs. Key topics included the application of novel pharmacokinetic end points to reduce study duration, the integration of community preferences into practice‐based research in resource‐limited settings, intellectual property considerations, formulation and manufacturing complexities that affect cost, scalability and implementation, and the growing role of model‐integrated evidence in streamlining bioequivalence assessments. To reach the goal of timely and equitable global access to long‐acting medicines, this workshop emphasized the need for strategic public‐private engagement to promote data sharing, enhance regulatory efficiencies, and develop robust in vitro–in vivo correlation strategies that meet regulatory guidance for LAI products.


  • Open Access

    The Promises and Prospects of Long-Acting Therapeutics for Treatment and Prevention of Infectious Diseases

    by Adeniyi Olagunju, Simone Perazzolo, Zachary R. Stephen, Mark Ryan, Xiaolin Xu, Prajith Venkatasubramanian, Shakir Atoyebi, Rachele Delle Fratte, Andrew Owen, Charles Flexner, et al.

    Long-acting (LA) therapeutics have emerged as a key component of infectious disease treatment and prevention strategies, their uptake fueled by the need to bridge notable gaps with short-acting drug formulations. In this review, we present the key drivers and summarize the enabling technologies. Focusing on infections with significant global disease burden (HIV, hepatitis B and C, tuberculosis, malaria, and COVID-19), the current state of knowledge on approved LA therapeutics and promising innovations currently in development are summarized. The potential role of LA therapeutics as countermeasures for diseases of pandemic potential and new approaches using computational modeling to accelerate their development for pediatric and perinatal health are discussed. Due to complexities in manufacturing, and the diversity of patent-protected technologies, barriers exist for global access to LA products and in upscaling intricate LA formulations. A multipronged strategic framework, including acceleration of equitable access through generic product manufacture, is proposed to realize the full potential of LA therapeutics for global health.


  • Open Access

    BRIDGING THE GAP FROM ACADEMIC RESEARCH TO COMMERCIALIZATION: LESSONS LEARNED FROM THE INTEGRATED ENTREPRENEURIAL TRAINING AND MENTOR-GUIDED PROJECT FUNDING AT WE-REACH

    by Terri Butler, Matthew H. Hartman, Tong Sun, Teddy Johnson, Fiona Wills, Ryan Buckmaster, Andy Stergachis, Rodney J. Y. Ho

    Academic research has produced an impressive array of life-changing health science innovations, including gene editing technologies, antibody therapeutics, infectious disease prevention technologie...

  • Long-acting Injectable Containing Lopinavir Eliminates Reliance on Ritonavir Pharmacokinetic Enhancement

    by Simone Perazzolo, Charles W Flexner, Zachary R Stephen, Edward P Acosta, Rachel A Bender Ignacio, Rodney J Y Ho

    High-extraction protease inhibitors (eg, for human immunodeficiency virus and severe acute respiratory syndrome coronavirus 2) typically require ritonavir to enhance bioavailability by overcoming first-pass metabolism. However, in the long-acting subcutaneous injectable dosage form TLC-ART 101, lopinavir persisted in plasma for 57 days, while ritonavir was detectable for only 3–7 days. The remarkable duration of lopinavir suggests that ritonavir may be unnecessary in long-acting injectable products, potentially reducing side effects and drug–drug interactions.


  • Open Access

    Drug Combination Nanoparticles Containing Gemcitabine and Paclitaxel Enable Orthotopic 4T1 Breast Tumor Regression

    by Jesse Yu, Xiaolin Xu, James Ian Griffin, Qingxin Mu, Rodney J. Y. Ho

    Early diagnosis, intervention, and therapeutic advancements have extended the lives of breast cancer patients; however, even with molecularly targeted therapies, many patients eventually progress to metastatic cancer. Recent data suggest that residual breast cancer cells often reside in the lymphatic system before rapidly spreading through the bloodstream. To address this challenge, an effective drug combination composed of gemcitabine (G) and paclitaxel (T) is administered intravenously in sequence at the metastatic stage, but intravenous GT infusion may limit lymphatic GT drug accessibility and asynchronous drug exposure in cancer cells within the lymph. To determine whether co-localization of intracellular gemcitabine and paclitaxel (referred to as GT) could overcome these limitations and enhance the efficacy of GT, we have evaluated a previously reported GT drug-combination formulated in nanoparticle (referred to as GT-in-DcNP) evaluated in an orthotopic breast tumor model. Previously, with indocyanine green-labeled nanoparticles, we reported that GT-in-DcNP particles after subcutaneous dosing were taken up rapidly and preferentially into the lymph instead of blood vessels. The pharmacokinetic study showed enhanced co-localization of GT within the tumors and likely through lymphatic access, before drug apparency in the plasma leading to apparent long-acting plasma time-course. The mechanisms may be related to significantly greater inhibitions of tumor growth—by 100 to 140 times—in both sub-iliac and axillary regions compared to the equivalent dosing with free-and-soluble GT formulation. Furthermore, GT-in-DcNP exhibited dose-dependent effects with significant tumor regression. In contrast, even at the highest dose of free GT combination, only a modest tumor growth reduction was notable. Preliminary studies with MDA-231-HM human breast cancer in an orthotopic xenograft model indicated that GT-in-DcNP may be effective in suppressing human breast tumor growth. Taken together, the synchronized delivery of GT-in-DcNP to mammary tumors through the lymphatic system offers enhanced cellular retention and greater efficacy.


  • Open Access

    Inoculation of Pan02 cells produces tumor nodules in mouse pancreas: Characterization of a novel orthotopic pancreatic ductal adenocarcinoma tumor model for interventional studies

    by James I. Griffin, Xinyue Chen, Luqi Duan, Qingxin Mu, Rodney J. Y. Ho

    Preclinical models of cancer are vital for assessing and predicting efficacies and toxicities of novel treatments prior to testing in human subjects. Current pancreatic tumor models exhibit variable growth rates, unpredictable tumor size after implantation in non-native tissues, or require surgical implantation. Surgical implantation in the pancreas may produce not only unpredictable tumor uptake but could also elicit additional inflammatory responses. In searching for a pancreatic carcinoma cell that can be introduced into a mouse via simple injection, we found that Pan02, a murine ductal pancreatic adenocarcinoma derived from a pancreatic lesion of a C57BL/6 mouse, inoculated peritoneally can consistently produce pancreatic tumors. This intraperitoneal, but not intravenous, introduction of Pan02 cells leads to the attachment and growth of Pan02 in the pancreas before spreading to other tissues. Time-course tissue analysis indicates that the Pan02 cells first find, infiltrate, and grow within the pancreas, producing a pancreatic tumor model. This model appears to mimic pancreatic cancer development in humans and is the first reported use of Pan02 cells to produce orthotopic pancreatic and metastatic neoplasms in a mouse model without the need for tumor implantation within matrices or survival surgeries. This orthotopic pancreatic tumor model, with consistent tumor uptake, synchronized tumor development and survival, and predictable outcomes may enable and accelerate the preclinical evaluation of treatment candidates for pancreatic cancer.